Clinical Trials Sponsored by Suzhou Yasheng Pharmaceutical Co., Ltd.

Total 4278 results

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors

Advanced Malignant Tumor

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study YL201 in Patients With Selected Advanced Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Small Cell Lung Cancer | Neuroendocrine Carcinoma

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Not yet recruiting

A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors

Solid Tumor
Suzhou Immunofoco Biotechnology Co., Ltd

Recruiting

A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Advanced Digestive System Tumor

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women

Osteoporosis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZGGS15 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Australia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Novel COVID-19-Infected Pneumonia

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZGGS18 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

Solid Tumors or Lymphoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Melanoma | Non Small Cell Lung Cancer | Cervical Carcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Advanced Solid Tumours
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Non-Small Cell Lung Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis

Psoriatic Arthritis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

KRAS G12C

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Acute Graft-Versus-Host Disease

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

Differentiated Thyroid Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study of IBI323 in Patients With Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Hepatocellular Carcinoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

CAR-T for r/r Malignant Tumors in Children

Child, Only | Malignant Tumor | CAR-T

China
Beta Pharma (Suzhou) Co., Ltd.

Recruiting

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Advanced Solid Tumor | HR+/HER2- Breast Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

Classic Hodgkin's Lymphoma

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Terminated

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

Schizophrenia

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Differentiated Thyroid Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Renal Impairment

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions

Myelofibrosis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

Hepatic Insufficiency | Healthy Subjects

China
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

Hypercholesterolemia

China
Suzhou Forlong Biotechnology Co.,Ltd,

Active, not recruiting

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Locally Advanced/Metastatic Solid Tumors

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Overweight Subjects | Obese Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Participants With Type 2 Diabetes

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI351 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China

Clinical Trials Sponsored by Suzhou Yasheng Pharmaceutical Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations